top of page


Est. 1970

Ciba began in 1859, when Alexander Clavel (1805–1873) took up the production of fuchsine in his factory for silk-dyeing works in Basel. By 1873, he sold his dye factory to the company Bindschedler and Busch. In 1884, Bindschedler and Busch was transformed into a joint-stock company named "Gesellschaft für Chemische Industrie Basel" (Company for Chemical Industry Basel). The acronym, CIBA, was adopted as the company's name in 1945.

The foundation for Geigy was established in 1857, when Johann Rudolf Geigy-Merian (1830–1917) and Johann Muller-Pack acquired a site in Basel, where they built a dyewood mill and a dye extraction plant. Two years later, they began the production of synthetic fuchsine.[49] In 1901, they formed the public limited company Geigy, and the name of the company was changed to J. R. Geigy Ltd in 1914.

Company History:

Ciba-Geigy is the largest chemical company in Switzerland. But since the country offers only a limited market and lacks many essential raw materials, Swiss chemical companies have been forced to enter foreign markets; and in order to compete successfully, they have had to lead the world in certain technologies.

In the early years of the twentieth century, the world's strongest chemical industries were in Germany, the United States, and Switzerland. German companies, fearful of losing their leading position to rapidly advancing American firms, openly colluded and coordinated business strategies. After World War I the German companies formed a cartel, the notorious IG Farben. In order to remain competitive with the Germans, the three largest Swiss chemical companies, Ciba Ltd., J.R. Geigy S.A., and Sandoz Ltd., formed a similar cartel called Basle AG. This trust lasted from 1918 to 1951. By 1970, however, market conditions led Ciba and Geigy to merge, forming one of the world's leading pharmaceutical and specialty chemical companies.

Geigy is the older of the two companies--one family member was in the drug business as early as 1758. Through several generations, the Geigy family had married into the prosperous silk manufacturing establishment in Basle and then became established in the dye trade in 1883. Only a few years later, the Geigy family set itself apart from other dyers in Basle by embracing newly discovered synthetic dying processes.

A few years earlier, in 1859, a French silk weaver named Alexander Clavel moved to Basle, where he established a dyeworks called the Gesellschaft für Chemische Industrie im Basle, or Ciba. In 1884 Clavel abandoned silk dying for a more lucrative trade in dyestuff manufacturing. Ciba gained a reputation for Fuchsine, a reddish purple dye, and Martius yellow.

By 1900 Ciba was the largest chemical company in Switzerland. With a major alkali works located at Monthey, it was one of the only Swiss manufacturers of inorganic dyes. Ciba, however, started a limited diversification into the pharmaceutical business with the introduction of an antiseptic called Vioform. Between 1900 and 1913 net assets quadrupled while profits nearly tripled. Geigy, during this period, remained steadfastly, committed to organic dye production; some of the dyes were still derived from coal tar.

Early in the century both Ciba and Geigy established factories in Germany, due in part to a labor shortage in Switzerland, but also to avoid enforcement of environmental laws designed to reduce pollution in the River Rhine.

Until World War I, German chemical companies dominated the world dye trade with a 90 percent market share. Those companies, including BASF, Hoechst, and Bayer, could easily have run Swiss competitors out of business through price competition; they had proven their ability to hold back the American chemical industry in its infancy. Instead, Ciba and Geigy developed practices that would permit international expansion while not provoking the Germans. Central to this strategy was the abandonment of bulk dye production (a German specialty) in favor of more expensive specialty dyes.

In time, the German companies developed a vested interest in the survival of their Swiss counterparts. Eighty percent of the raw materials used by the Swiss companies came from Germany. In eliminating Swiss competitors, the German companies would eliminate customers whose capacity they could not economically absorb. Furthermore, competition among German companies to fill a sudden void left by the Swiss could have destabilized the careful balance maintained by the cartel. As Swiss companies became acclimated to the German system, they were granted certain privileges, such as an exclusive right to export to Germany. Cooperation between Swiss and German companies also took the form of an occasional profit-sharing pool, as the one that existed between Geigy, Bayer, and BASF for black dye.

The onset of World War I in Europe in 1914 severely upset the equilibrium that had existed between Ciba, Geigy, and their German counterparts. Unable to secure raw materials and chemical intermediaries from German suppliers, factories in Basle were forced to suspend dye production. The Swiss later negotiated an agreement with the British, who had been dependent on German dyes and were unprepared for their trade embargo. The British agreed to supply the Swiss with raw materials on the condition that Swiss dyes would be sold preferentially to Britain. While Swiss factories in Baden were seized by the German government, the Swiss were free to export to the lucrative (and formerly German) markets in Britain and the United States and to establish factories in France and Russia.

Ciba's profits increased dramatically, from SFr 3 million in 1913 to SFr 15 million in 1917. The end of the war, however, reopened world markets, but left the industry in a severe state of overcapacity. By 1921 Ciba's profits had fallen to SFr 1 million. At this time the German companies decided to reform their cartel, this time under the aegis of a large holding company called IG Farben. Ciba, Sandoz, and Geigy were invited to join IG Farben but, true to Swiss neutrality, elected instead to form their own cartel, Basle AG.

Basle AG, founded in 1918, was fashioned after IG Farben. The group consisted of Ciba, Geigy, and Sandoz--virtually the entire Swiss chemical industry. The agreement mandated that all competition between the three companies would cease, technical knowledge would be freely shared, and all profits would be pooled. Ciba would receive 52 percent of the group's profits, while Geigy and Sandoz would each be entitled to 24 percent. Any sales between the companies were to be invoiced at cost, raw materials would be purchased jointly, and the manufacture of any product would be assigned to whichever company could produce it at the lowest cost.

From the cartel's inception, Geigy's weak market position was a source of tension for its partners. Geigy still produced vegetable dyes, which were gradually losing market share to organic dyestuffs. Despite Sandoz's contention that it was being forced to subsidize Geigy, Basle AG remained stable. In fact, it was considered more successful than the larger and more powerful IG Farben. All three firms invested their profits into a broader range of chemical interests, including chemicals and pharmaceuticals. By 1930 these divisions contributed more than one quarter of the group's profits. A joint venture between Sandoz and Geigy led to the establishment of the Cincinnati Chemical Works, a subsidiary that gave Basle AG a tariff-free foothold in the American market.

In 1929, placing profit before independence, Basle AG joined with IG Farben to create the Dual Cartel. French dyemakers joined the group shortly afterwards, forming the Tripartite Cartel. In 1932, with the addition of the British cartel Imperial Chemical Industries, the group was again renamed the Quadrapartite Cartel. This pan-European cartel existed until 1939, when World War II forced its dissolution.

Due to the secrecy characteristic of Swiss firms, little is known about Basle AG's activities during the war; the company had subsidiaries in both Allied and Axis nations. At one point, Ciba angered its partners by placing its shares in Cincinnati Chemical Works under the custody of an American trust. Apparently fearing the eventual seizure of those shares by the alien property custodian, Geigy and Sandoz protested in American courts but were unable to retrieve Ciba's shares.

In 1940 Dr. Paul Mueller, a researcher with Geigy, discovered the insecticidal properties of DDT. Originally thought safe enough to be sprayed directly on refugees to eradicate lice, DDT was considered a "wonder chemical." Research during the war led to the development of several ethical drugs, including Privine, a treatment for hay fever, and Nupercaine, a spinal anesthetic used in childbirth. The companies also developed drugs for treatment of high blood pressure and heart disease.

After the war Ciba notified Geigy and Sandoz that as a result of U.S. antitrust laws, the 1918 agreement could not be respected among subsidiaries in the United States. Geigy made a similar declaration regarding American assets in 1947. Two years later Sandoz again raised the issue of cross-subsidization and proposed that the cartel be dissolved. Geigy opposed the motion, but Ciba, unwilling to abandon its lucrative markets in the United States, eventually sided with Sandoz; the postwar environment no longer justified cartelization for self-protection. Basle AG was finally dissolved in 1951.

Geigy's poor financial performance called into question its survivability outside the cartel. During the 1950s, however, the full market potential of DDT was realized. Suddenly profitable, Geigy expanded its market in agri-chemicals by introducing a corn herbicide called triazine.

Both Ciba and Geigy grew steadily during the 1950s. Between 1950 and 1959, Ciba's sales grew from SFr 531 million to SFr 1026 million, and Geigy's grew from SFr 260 million to SFr 738 million. By 1960 both Ciba and Geigy were diversified manufacturers, competing directly in pharmaceuticals, dyes, plastics, textile auxiliaries, and agricultural and specialty chemicals. Each year Geigy's sales grew stronger, until in 1967 the company overtook Ciba.

Although older than Ciba by 25 years, Geigy maintained a more youthful image. While Ciba sold itself as the company "where research is the tradition," Geigy recruited engineers with the slogan, "future with Geigy." But in 1970, while Ciba and Geigy personnel were quibbling over their respective talents, the leaders of both companies were discussing a possible merger.

The idea to merge was first raised when the two companies jointly established a factory at Toms River, New Jersey. With increasingly difficult conditions in export markets--particularly the United States--officials of the two companies began to explore the benefits of combining their textile and pharmaceutical research; Geigy's strength in agricultural chemicals complemented Ciba's leading position in synthetic resins and petrochemicals.

Ciba and Geigy were both in excellent financial condition. However, some of the same market conditions that had led them to form Basle AG in 1918 were once again prevalent. Competition against German companies in export markets had intensified. But it was as a defense against emerging petrochemical industries in oil-rich Persian Gulf states that the merger was most attractive.

The largest obstacle to a merger between Ciba and Geigy was U.S. antitrust legislation. Antitrust sentiment in the United States was so strong that federal prosecutors vowed to block the merger in Switzerland if it threatened to restrain American trade in any way. In order to win approval in the United States, Ciba agreed to sell its American dyeworks to Crompton and Knowles, and Geigy consented to turn over its American pharmaceutical holdings to Revlon. Despite further challenges, including one from consumer advocate Ralph Nader, the merger was approved.

Mechanically, the merger consisted of a takeover of Ciba by Geigy. This was done to minimize tax penalties amounting to SFr 55 million. Geigy's chairman, Dr. van Planta, assumed the chairmanship of the new company, with Ciba's chairman, Dr. Kappeli, serving as honorary chairman.

As promised, the Ciba-Geigy merger has proven "synergistic." The more profitable but less diversified Geigy has benefited from Ciba's research capabilities. Ciba, on the other hand, has profited from Geigy's more modern approach to marketing and management. In the United States, the company's American subsidiary passed the one billion dollar sales mark in 1978, and doubled that figure only six years later. The company's worldwide sales that year were SFr 17.5 billion, 30 percent of which came from U.S. operations. Despite a 14 percent drop in profits between 1978 and 1980, Ciba-Geigy has maintained strong annual sales growth since 1981; profits as a percentage of sales was 8.1 percent in 1985.

In contrast to its impressive performance on the balance sheet, Ciba-Geigy has suffered a few problems with its public image. In the mid-1970s a Ciba-Geigy product marketed in Africa as an ordinary analgesic produced a horrifying side-effect: the loss of large pieces of flesh. In addition, its plant at Toms River discontinued production of Posgene in response to a Greenpeace campaign that warned the community of a possible accident similar in magnitude to the tragedy in Bhopal, India.

Troubles at Toms River continued: in 1982 the plant was added to the U. S. Environmental Protection Agency's (EPA) list of "Superfund" cleanup sites when more than 120 chemicals were discovered in local groundwater. Then, in 1984, investigators found a leak in the ten-mile conduit leading from Ciba's facility. The company discontinued dye, resin, and additive production at Toms River in 1986 and pleaded guilty to one charge of illegal waste disposal in March of 1992. The corporation paid more than $60 million in fines and landfill and groundwater cleanup costs and agreed to make donations to New Jersey state conservation projects. The Toms River experience, combined with tightening European Community pollution regulations, helped convince Ciba-Geigy to cite the environment as one of its focuses.

Environmentalism became one of the cornerstones of Ciba's "Vision 2000" strategy, a long-term plan to balance the economic, social, and environmental objectives of the company. The company logo was shortened to just "ciba," but the formal name remained unchanged. The corporation was reorganized from functional/geographical units into 14 separate businesses with autonomous research and development, production, and marketing divisions. Ciba's businesses could be grouped into three basic areas: healthcare, agriculture, and industry.

The company considered its Pharma, Plant Protection, and Additives divisions primary businesses. Pharma, the single largest operating unit, ranked among the world's top five pharmaceutical concerns. The corporation's leading product was Voltaren, an anti-rheumatic. Ciba's Pharma unit also claimed the second most popular smoking cessation patch, Habitrol (known as Nicotinell outside the United States). Habitrol encountered stiff competition in the 1990s, but was launched in France and Canada in 1992 and received over-the-counter status in the United Kingdom and Italy that year. One problem with transdermal nicotine patch sales was that the product created a self-defeating market: if the treatment worked, patients would eventually end the therapy; if the patches were ineffective, smokers would not buy them. Ciba-Geigy purchased the Dr. R. Maag plant protection business from Hoffman-La Roche in 1990 and achieved majority ownership of Bunting Group's plant protection business in 1992.

Ciba-Geigy's Self Medication, Diagnostics, and Ciba Vision units were recognized by the corporation as growth enterprises. Self Medication was expanded with the 1992 acquisition of Fisons' North American business, and the purchase of Triton Diagnostics buttressed the Diagnostics group. Ciba Vision's contact lenses, lens care products, and ophthalmic medicines ranked number two worldwide.

Ciba-Geigy's Seeds and Composites units were considered long-term investments. In 1990, the company announced that it had successfully inserted marker genes into corn cells that produced fertile plants and passed the new traits on to viable seeds. The company thereby entered the race to genetically engineer plants with the most attractive traits.

The core industrial businesses of Ciba-Geigy in the early 1990s included Textile Dyes, Chemicals, Pigments, Polymers, and Mettler Toledo scales. The leading market positions of these businesses allowed them to function as "cash cows" for research and development in other areas. For example, Ciba's textile dyes, additives, and Mettler Toledo units ranked number one worldwide in their respective categories.

Ciba's reorganization included the divestment of its Flame Retardants and Water Treatments Chemicals businesses, valued at approximately $100 million. The units were sold to FMC Corp. in 1992. Ciba-Geigy's sales and profits increased steadily in the late 1980s and early 1990s to reach 1992 figures of more than SFr 22 billion in revenue and SFr 1.52 billion in profits. The majority of Ciba's sales, 36 percent, were made in European Community countries. Overall European sales comprised 43 percent of the total, while North America contributed 32 percent, Asia constituted 13 percent, and Latin America made up 7 percent.

Ciba-Geigy is one of the five largest chemical companies in the world. And, while it is widely diversified within the industry, it has maintained a steady emphasis on sophisticated chemicals--whether they are pharmaceuticals, plastics, pigments, or pesticides. (Until it was sold, Airwick, which made air fresheners and other consumer products, was one of Ciba-Geigy's very few low-tech ventures.) The company had plans to strengthen existing product lines and limit diversification to compatible high-technology operations in biotechnology, laser applications, and diagnostics.

Principal Subsidiaries:

Ciba-Geigy International AG, Ciba-Geigy SA, Centre de recherches agricoles; Ciba-Geigy Munchwilen AG, Ciba-Geigy Verkaufs-und Vertriebsgesellschaft AG; Ciba-Geigy Services AG, Ciba-Geigy Handels-und Marktberatungs AG; Compagnie des Forces Motrices d'Orsieres; Mettler Toledo AG, Zyma SA, Dispersa AG; Ciba Vision Management AG; Dr R. Maag AG; Ciba-Geigy PLC (United Kingdom); Ciba-Geigy PLC (United Kingdom); Societe Anonyme Ciba-Geigy (France); Laboratoires Ciba-Geigy SA (France); La Quinoleine SA (France); Ciba-Geigy GmbH (Germany); Pfersee Chemie GmbH (Germany); Ciba-Geigy Marienberg GmbH (Germany); Ciba-Geigy Holding Deutschland GmbH (Germany); Ciba-Geigy S.p.A. (Italy); Chemical Insurance Company Limited (Bermuda); Befico Ltd. (Bermuda); Ciba-Geigy Finance and Investment Limited (Bermuda); Ciba-Geigy Canada Limited; Ciba-Geigy Corporation (U.S.A.); Ciba Corning Diagnostics Corp. (U.S.A.); Geneva Generics Inc. (U.S.A.); Ohaus Scale Corp. (U.S.A.); OCG Microelectronic Materials, Inc. (U.S.A.); Sociedade Agricola Germinal Ltda. (Brazil); Ciba-Geigy Mexicana, SA de CV.; Ciba-Geigy (Japan) Limited; Ciba-Geigy (Malaysia) Sendirian Berhad; Ciba-Geigy (Pty.) Limited (South Africa), Ciba-Geigy Australia Limited (Australia).

bottom of page